Dihydromyricetin

Phase 1Small molecule

UUniversity of Southern California

Dihydromyricetin is one of 55 small molecule programs targeting Liver Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver DiseaseNot yet recruiting

Liver DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

99 competitors in Liver Disease

#DrugCompanyPhaseTrials

Kalydeco

Vertex Pharmaceuticals

Piqray

Balversa

Cibinqo

Nourianz

Kyowa Kirin Co., Ltd.

Fabhalta

Rydapt

Lenvima

Opzelura

Lazcluze

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Disease1 trial

Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease

Not yet recruiting·UUniversity of Southern California·Phase 1·NCT05623501·12 enrolled

Type 2 Diabetes Mellitus1 trial

Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus

Unknown status·UUniversity of Guadalajara·Phase 2·NCT03606694·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dihydromyricetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dihydromyricetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dihydromyricetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Southern California

Dihydromyricetin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Disease1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News